Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Phase 4 Completed 100 enrolled Almirall, S.A. Allergan · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.

Timeline

Start: 2016-10-31
Primary completion: 2018-03-09
Completion: 2018-03-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapsone	Small molecule	7.5 %	Topical

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Summary

Timeline

Drugs

Indications